StockNews.AI
LLY
StockNews.AI
26 days

INSERTING and REPLACING Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines

1. Gate Bioscience's deal could reach $856 million with milestone payments. 2. This partnership may enhance LLY's product pipeline and revenue potential.

2m saved
Insight
Article

FAQ

Why Bullish?

Collaborations with milestone payments can enhance stock performance, reminiscent of previous partnerships that boosted forecasts.

How important is it?

The announcement of a substantial collaboration can generate investor interest and confidence in LLY’s growth.

Why Long Term?

Long-term revenue growth from successful product development may take years, aligning with LLY's strategic goals.

Related Companies

PFEABBV
BRISBANE, Calif.--(BUSINESS WIRE)--Insert updated third paragraph, first sentence of release: Under the terms of the agreement, Gate will receive an upfront payment and equity investment and will be eligible to receive milestone payments upon achievement of certain development, regulatory, and commercial milestones, as well as tiered royalties on global net sales, with a total deal value up to $856 million. The updated release reads: GATE BIOSCIENCE ENTERS INTO A COLLABORATION AND LICENSE AGREE.

Related News